Headlines about Allergan plc (NYSE:ACT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan plc earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.1913834312895 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern’s analysis:

Allergan plc (ACT) opened at 299 on Friday. The company has a 50-day moving average price of $297.00 and a 200-day moving average price of $285.00. Allergan plc has a 1-year low of $202.00 and a 1-year high of $318.00.

TRADEMARK VIOLATION NOTICE: “Allergan plc (ACT) Getting Somewhat Favorable Press Coverage, Study Finds” was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/09/16/allergan-plc-act-getting-somewhat-favorable-press-coverage-study-finds.html.

Allergan plc Company Profile

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business.

Insider Buying and Selling by Quarter for Allergan plc (NYSE:ACT)

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.